Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor

NCT01948843 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT01948843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01948843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor
Lead sponsor
Polaris Group
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2014
Completion date
April 30, 2016
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 negative metastatic breast cancer